More about

Car T-Cell Therapy

News
April 21, 2023
3 min read
Save

Allogeneic CAR-T provides tumor control in advanced kidney cancer

Allogeneic CAR-T provides tumor control in advanced kidney cancer

A single infusion of ALLO-316 provided a high rate of disease control for patients with advanced or metastatic renal cell carcinoma, results from the phase 1 TRAVERSE trial showed.

News
April 13, 2023
3 min read
Save

Despite access barriers, physicians prefer CAR-T for treatment of advanced B-cell lymphoma

Despite access barriers, physicians prefer CAR-T for treatment of advanced B-cell lymphoma

Physicians recommended chimeric antigen receptor T-cell therapy more frequently than any other regimen for third-line treatment of relapsed or refractory diffuse large B-cell lymphoma, survey results showed.

News
March 29, 2023
6 min read
Save

Community physicians play essential role in long-term care after CAR-T

Community physicians play essential role in long-term care after CAR-T

Despite an overall positive safety outlook, the scope of potential toxicities related to chimeric antigen receptor T-cell therapy remains unclear due to lack of long-term follow-up.

News
March 19, 2023
1 min read
Save

American Society for Transplantation and Cellular Therapy names president

American Society for Transplantation and Cellular Therapy names president

Miguel-Angel Perales, MD, has been named president of American Society for Transplantation and Cellular Therapy for 2023-2024.

News
March 17, 2023
1 min read
Save

Carl H. June, MD, to receive AACR lifetime achievement award

Carl H. June, MD, to receive AACR lifetime achievement award

Carl H. June, MD, will receive this year’s AACR Award for Lifetime Achievement in Cancer Research.

News
March 15, 2023
1 min read
Save

Bellicum Pharmaceuticals ends CAR-T trials for solid tumors after risk-benefit review

Bellicum Pharmaceuticals ends CAR-T trials for solid tumors after risk-benefit review

Bellicum Pharmaceuticals discontinued clinical trials for two investigational chimeric antigen receptor T-cell therapies, the company announced today.

News
February 28, 2023
1 min read
Save

CAR T-cell therapy, new drugs ushering in ‘lupus renaissance’

CAR T-cell therapy, new drugs ushering in ‘lupus renaissance’

SCOTTSDALE, Ariz. — Several new drugs and promising therapies, including chimeric antigen receptor T-cell therapy, have ushered in a “lupus renaissance,” said a speaker at the Basic and Clinical Immunology for the Busy Clinician symposium.

News
February 23, 2023
2 min read
Save

Gut microbiome data can predict response to CAR-T for multiple myeloma

Gut microbiome data can predict response to CAR-T for multiple myeloma

Researchers developed a highly accurate model that can predict which patients will achieve complete response to chimeric antigen receptor T-cell therapy for multiple myeloma.

News
February 21, 2023
4 min read
Save

Healio | HemOnc Today announces new physician leadership

Healio | HemOnc Today is excited to announce a new physician leadership structure, which features seven Associate Medical Editors from various subspecialty areas within oncology and hematology.

News
February 20, 2023
3 min read
Save

New treatment target emerges for those who relapse after CAR-T for lymphoma

New treatment target emerges for those who relapse after CAR-T for lymphoma

A novel chimeric antigen receptor T-cell therapy induced response among adults with advanced large B-cell lymphoma who relapsed after previous CAR-T, study results showed.

View more